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Background and Aim: A recently carried out randomized
controlled trial showed the benefit of a novel 20-G fine-
needle biopsy (FNB) over a 25-G fine-needle aspiration (FNA)
needle. The current study evaluated the reproducibility of
these findings among expert academic and non-academic
pathologists.
Methods: This study was a side-study of the ASPRO (ASpira-
tion versus PROcore) study. Five centers retrieved 74 (59%)
consecutive FNB and 51 (41%) FNA samples from the ASPRO
study according to randomization; 64 (51%) pancreatic and 61
(49%) lymph node specimens. Samples were re-reviewed by five
expert academic and five non-academic pathologists and rated
in terms of sample quality and diagnosis. Ratings were
compared between needles, expert academic and non-aca-
demic pathologists, target lesions, and cytology versus histo-
logical specimens.
Results: Besides a higher diagnostic accuracy, FNB also
provided for a better agreement on diagnosing malignancy
(K = 0.59 vs K = 0.76, P < 0.001) and classification according to
Bethesda (K = 0.45 vs K = 0.61, P < 0.001). This equally applied
for expert academic and non-academic pathologists and for
pancreatic and lymph node specimens. Sample quality was also
rated higher for FNB, but agreement ranged from poor
(K = 0.04) to fair (K = 0.55). Histology provided better agree-
ment than cytology, but only when a core specimen was
obtained with FNB (P = 0.004 vs P = 0.432).
Conclusion: This study shows that the 20-G FNB outperforms
the 25-G FNA needle in terms of diagnostic agreement,
independent of the background and experience of the pathol-
ogist. This endorses use of the 20-G FNB needle in both expert
and lower volume EUS centers.
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INTRODUCTION
TRADITIONALLY, ENDOSCOPIC ULTRASOUND(EUS)-guided tissue sampling has been carried out
using a thin and ﬂexible ﬁne-needle aspiration (FNA)
needle, which mainly yields individual cells (cytology)
rather than histologically intact tissue fragments. Although
diagnostic accuracy rates of FNA are fair, intact tissue
fragments are preferred to enable identiﬁcation of tumor
invasion and allow for ancillary immunological and molec-
ular testing; for example, in submucosal and neuroendocrine
tumors.1–9 Furthermore, histology enables genetic proﬁling
and a patient-tailored approach, which is becoming increas-
ingly relevant in this era of personalized medicine.10–14 The
growing need for histology resulted in the introduction of
ﬁne-needle biopsy (FNB) needles.
So far, most studies reported an equal performance of FNA
and FNB needles,6–9,15 but, recently, two large randomized
trials showed a signiﬁcant diagnostic beneﬁt of FNB.16,17
One of these studies, the randomized controlled ASPRO
(ASpiration vs PROcore) trial, was carried out in 13 EUS
clinics, worldwide.17 This study showed a diagnostic beneﬁt
of a novel 20-G FNB needle (ProCore; Cook Medical,
Bloomington, IN, USA) over the widely used 25-G FNA
needle (EchoTip Ultra; Cook Medical), irrespective of lesion
type, size, and the number of passes carried out. However,
general applicability of these ﬁndings cannot be warranted,
as study participation was conﬁned to expert centers only.
Ideally, the superiority of a diagnostic device is repro-
ducible in expert and non-expert hands. Therefore, the
present study compares the diagnostic agreement on sam-
ples obtained with the novel 20-G FNB to the 25-G FNA
needle among expert academic pathologists and non-
academic pathologists.
METHODS
Study design
IN THE COURSE of the ASPRO trial (ClinicalTrials.gov:NCT02167074), 13 EUS centers randomized 608 con-
secutive patients with a solid pancreatic lesion, lymph node,
or submucosal or other solid lesion to sampling with a 20-G
FNB (ProCore; Cook Medical) or with a 25-G FNA needle
(EchoTip Ultra; Cook Medical), between February 2015 and
September 2016. Parameters regarding specimen character-
istics and diagnostic accuracy were compared. Gold stan-
dard diagnosis was based on the prior ASPRO study17 either
on pathological evaluation of the surgical resection speci-
mens or on clinical follow up for at least 9 months when
surgical resection was not indicated. Gold standard
diagnosis was recorded by the principal investigator of
each of the participating centers.
For the present side-study, the ﬁrst 125 pancreatic and
lymph node cases that were enrolled in the ASPRO study
were included. Samples from these cases were reassessed by
ﬁve expert academic and ﬁve non-academic pathologists.
Diagnosis of malignancy and quality scores were assessed,
and agreement on these outcome measures was compared
between the two needles and between academic and non-
academic pathologists.
As our study was a clinical trial, all authors could access
the study data and have reviewed and approved the ﬁnal
manuscript.
Center, pathologist and case selection
ASpiration versus ProCore study centers were invited to
contribute to this study if they had collected at least 20 solid
pancreatic and lymph node samples by April 2016, and their
pathologist was trained to read both cytology and histology.
Five ASPRO study centers fulﬁlled these criteria (Milan,
Osaka-Sayama, Rome, Rotterdam, and Santiago de Com-
postela). Each center was represented by the specialized
‘academic’ pathologist who was also involved in the
original ASPRO study. This academic pathologist invited
a ‘non-academic’ colleague from a local community practice
hospital with a general clinical proﬁle to participate. Expert
academic pathologists had reviewed between 3000 and
40 000 EUS samples, including both FNA and FNB during
their career, whereas the non-academics had a sample
review track record of between 50 and 1000. Per case, the
academic pathologists selected the minimum number of
slides required to obtain a tissue diagnosis, including
immunohistochemically stained slides, if available.
Endoscopic ultrasonography-guided tissue
sampling
Endoscopic ultrasonography procedures were carried out
with a convex array echoendoscope (either Pentax EG-3870
UTK or EG-3270UK; Pentax, Tokyo, Japan, or Olympus
UTC 140/180/260; Olympus, Tokyo, Japan) as described in
the ASPRO study.17 Three study sites had on-site patho-
logical evaluation at their disposal (Milan, Rotterdam, and
Santiago de Compostela).
Specimen processing
Tissue samples were preserved according to local practice.
Cytological tissue sampleswere smeared onto glass slides and
stained with (Diff Quick, RAL diagnostics) or hematoxylin
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and eosin (HE) staining (Milan, Osaka-Sayama, Rome).
Remainder of the cytological specimens were collected in
(CytoLyt, ThinPrep CytoLyt Solution, Marlborough, MA,
USA), saline (Osaka-Sayama), or formalin (Milan). Cell
suspensions were processed into cell blocks using the
(Cellient automated cell block system Hologic,Toronto,
Canada) or agar technique (Milan, Rome, Santiago de
Compostela). Osaka-Sayama did not further process cytology.
Histology was collected in CytoLyt (Santiago de Compostela
andRotterdam) or formalin (Milan,Rome,Rotterdam,Osaka-
Sayama). Samples collected in formalin were processed as
parafﬁn blocks, sectioned at 3–4 microns, and stained with
HE for morphological evaluation.
Review session
Cases were reviewed during a 2-day session at the Erasmus
MC University Medical Center Rotterdam, the Netherlands
in April 2016. Each expert academic pathologist presented
the selected cases providing information on the patient’s
gender, age and relevant medical history, type of target
lesion (lymph node or solid pancreatic lesion) and a
summary of the EUS report. Pathologists were blinded for
the ﬁnal clinical and pathological outcomes. Slides were
viewed simultaneously using a multi-headed light micro-
scope, but assessed individually. Slides, representative of a
case, were presented, including immunohistochemically
stained slides, if available. Each pathologist reviewed all
cases, including their own.
Outcome measures and definitions
Primary outcome measure was to compare the diagnostic
agreement on samples obtained with the two needles. First,
samples were assessed for malignancy (yes/no) and classi-
ﬁed according to Bethesda (non-diagnostic, benign, atypi-
cal/suspect malignancy, and malignant).18 Solid-
pseudopapillary neoplasms were classiﬁed as malignant.
Neuroendocrine and spindle cell tumors were classiﬁed as
malignant only if they harbored high-grade dysplasia or an
invasive component. Second, we evaluated whether diag-
nostic agreement for the two needles differed between
expert academic and non-academic pathologists, between
pancreatic and lymphatic lesions, and between specimens
containing cytology and histology.
Furthermore, agreement on specimen quality parameters
was assessed and compared between the two needles, and
between expert academic and non-academic pathologists.
The following quality parameters were scored: presence of
artifacts, sample sufﬁciency, presence of target cells and
tissue cores and suitability for additional analysis. Artifacts
were subdivided into ﬁve categories: poor ﬁxation or drying
artifacts, thick smears, blood clots, contamination with other
cells (mesothelial, liver, gastric or intestinal epithelium), and
other. Sample sufﬁciency was deﬁned as the presence of
sufﬁcient target cells to obtain or exclude a certain
diagnosis. Target cells were classiﬁed as less or more than
50%. Presence of tissue core was deﬁned as the presence of
a measurable microscopic cylinder containing target organ
cells with preserved histological structure.
Last, we assessed if and to what extent pathologist’s
experience or specimen characteristics inﬂuenced diagnostic
accuracy.
Statistical analysis
The sample size for this studywas derived fromWalteret al.19
Given the availability of 10 observers (ﬁve academic and ﬁve
non-academic pathologists), 50 samples are needed to be
analyzed per needle type (50 9 2 = 100 in total), given a
one-sided alpha of 0.05, a power of 80%, a minimally
acceptable interrater reliability of 0.6 for agreement on the
presence of malignancy, and a minimal deviation from the
interrater reliability of 0.2 between the two needles, n = 10.
Interobserver agreement was calculated by the use of kappa
statistics Fleiss’ j-statistic and 95% conﬁdence intervals (CI).
Kappa-statistics were interpreted according to the convention
of Landis and Koch: <0, no agreement; 0–0.20, slight
agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, substantial agreement; and 0.81–1.0,
almost perfect agreement. The chi-squared test was used to
compare the diagnostic agreement between the two study
needles, academic and non-academic pathologists, target
lesion types, and cytological and histological samples.
Although all 10 observers assessed the samples for each of
the outcome parameters, we reported only the average
outcome per parameter. Last, univariate logistic regression
analysis was applied to assess whether a pathologist’s
expertise and sample quality inﬂuenced diagnostic accuracy.
Outcomes of this analysis are expressed as odds ratio (OR)
with 95% CI. Statistical signiﬁcance was deﬁned as P < 0.05
(two-tailed). Analyses were carried out using SAS version 9.4
(SAS Institute, Cary, NC, USA), and SPSS version 22,
Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Target lesion and procedure characteristics
ATOTAL OF 125 samples were reviewed, of which 74were collected by FNB (59%) and 51 by FNA (41%),
with a mean of 2.8 needle passes. Sixty-four were solid
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pancreatic lesions (51%) and 61 were lymph nodes (49%)
with a mean size of 30.4  1.3 mm. Table 1 shows the case
and sampling speciﬁcs. Techniques intended to increase the
sample yield were applied in 94% of cases; suction with a
syringe in 74 (63%), the slow-pull technique in 50 (37%),
and a combination of the two in ﬁve (4%). The gold
standard diagnosis comprised 26 (21%) non-malignant cases
and 99 (79%) malignant cases (Table 1). The gold-standard
diagnosis was based on surgical resection specimens in 31
cases (25%).
Diagnostic accuracy and agreement
In line with the ASPRO study results, FNB samples
provided higher accuracy than FNA for malignancy (88%
vs 77%, P = 0.002) and classiﬁcation according to Bethesda
(76% vs 61%, P = 0.002). Regarding the primary question
of diagnostic agreement, FNB samples provided better
agreement on the presence of malignancy (j = 0.76 vs 0.59,
P < 0.001) and classiﬁcation according to Bethesda
(j = 0.61 vs 0.45, P < 0.001, Table 2). This was true for
both expert academic and non-academic pathologists
(Table 2).
Assessment per target lesion showed that for lymph
nodes, FNB provided higher agreement on the presence of
malignancy and classiﬁcation according to Bethesda. How-
ever, in pancreatic lesions, FNB only outperformed FNA for
agreement on the Bethesda classiﬁcation, not for the
presence of malignancy (Table 3). When comparing histol-
ogy to cytology, agreement on the presence of malignancy
was better for histological samples, but agreement on the
Bethesda classiﬁcation was better for histological samples
only if they had been obtained with the FNB needle
(Table 4).
Specimen quality and agreement
Compared to FNA, FNB samples contained fewer artifacts
(52% vs 45%, P = 0.007, Table 2), but agreement was low
for both FNB (j = 0.10; 95% CI 0.07–0.14) and FNA
samples (j = 0.17; 95% CI 0.13–0.21). Agreement did not
differ between expert academic and non-academic pathol-
ogists for FNA (P = 0.132) or FNB (P = 0.212). Sample
sufﬁciency for diagnosis, percentage of target cells, presence
of tissue cores, and suitability for additional analysis were
all better for FNB than for FNA, but, again, agreement on
these parameters was poor (K = 0.04) to fair (j = 0.55,
Table 2). As for the collection of histology, use of FNB
provided histological samples more often than did FNA
(70% vs 36%, P < 0.001, Table 2). Agreement on all of the
above-mentioned quality parameters was highest for the
expert academic pathologists. Furthermore, agreement
among the expert academic pathologists was higher for
FNB than for FNA specimens. In non-academic patholo-
gists, however, FNB provided for better agreement than
FNA only for the identiﬁcation of tissue cores (j = 0.26 vs
0.04, P < 0.001).
Table 1 Characteristics of samples obtained with the novel 20-
G FNB vs the 25-G FNA needle among expert academic
pathologists and non-academic pathologists
Variable, n (%) All
(n = 125)
FNB
(n = 74)
FNA
(n = 51)
Center of origin
Rotterdam 33 (26) 23 (31) 10 (20)
Rome 30 (24) 20 (27) 10 (20)
Milan 22 (18) 11 (15) 11 (22)
Santiago de
Compostela
20 (16) 10 (14) 10 (20)
Osaka-Sayama 20 (16) 10 (14) 10 (20)
Target lesion
Solid pancreatic
lesion
64 (51) 39 (53) 25 (49)
Lymph node 61 (49) 35 (47) 26 (51)
Size (mm),
mean  SD
30.4  1.3 31.5  1.8 28.8  1.8
Location of pancreatic lesions
Head 40 (62) 28 (72) 12 (48)
Neck 5 (8) 2 (5) 3 (12)
Corpus 12 (19) 7 (18) 5 (20)
Tail 7 (11) 2 (5) 5 (20)
Location of lymph nodes
Mediastinal 21 (34) 14 (40) 7 (14)
Abdominal 40 (66) 21 (60) 19 (73)
Gold standard diagnosis
Benign, normal
tissue
18 (14) 14 (19) 4 (8)
Sarcoidosis 1 (1) 0 (0) 1 (2)
Pancreatitis 2 (2) 1 (1) 1 (2)
Leiomyoma 1 (1) 0 (0) 1 (2)
GIST, low grade 2 (2) 0 (0) 2 (4)
NET low grade 2 (2) 1 (1) 1 (2)
NET high grade 4 (3) 3 (4) 1 (2)
Leiomyosarcoma 1 (1) 1 (1) 0 (0)
Solid
pseudopapillary
neoplasm
3 (2) 2 (3) 1 (2)
Metastatic disease 13 (10) 6 (8) 7 (13)
Malignant
lymphoma
11 (9) 5 (7) 6 (12)
Adenocarcinoma 67 (54) 41 (55) 26 (51)
FNA, fine-needle aspiration; FNB, fine-needle biopsy; GIST, gastroin-
testinal stromal tumor; NET, neuroendocrine tumor.
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Factors affecting diagnostic accuracy
Besides the type of needle, other factors affecting EUS-
sample diagnosis are shown in Table 5. A pathologist’s
background (expert academic or non-academic) did not
inﬂuence the diagnostic accuracy of either needle
(P = 0.250). Presence of artifacts did have an effect, as this
resulted in a lower diagnostic accuracy (P = 0.030). Last,
Table 2 Agreement on sample diagnosis and quality among the pathologist groups per needle type
Cases scored as FNB (n = 74) FNA (n = 51) P-value
Malignant – no. (%) 47 (64) 27 (53) <0.001
Agreement – j (95% CI)
All 0.76 (0.73–0.79) 0.59 (0.55–0.63) <0.001
Expert academic 0.74 (0.66–0.81) 0.54 (0.45–0.62) <0.001
Non-academic 0.78 (0.71–0.85) 0.64 (0.55–0.72) <0.001
Bethesda classification – no. (%)
Non-diagnostic 6 (8) 8 (16) <0.001
Benign 9 (12) 3 (6)
Neoplastic 12 (16) 13 (26)
Malignant 47 (64) 27 (53)
Agreement – j (95% CI)
All 0.61 (0.60–0.64) 0.45 (0.43–0.48) <0.001
Expert academic 0.62 (0.57–0.67) 0.43 (0.37–0.49) <0.001
Non-academic 0.59 (0.55–0.64) 0.46 (0.40–0.52) <0.001
Sufficient quality – no. (%) 67 (91) 40 (78) <0.001
Agreement – j (95% CI)
All 0.49 (0.46–0.53) 0.48 (0.44–0.52) 0.366
Expert academic 0.50 (0.43–0.58) 0.33 (0.28–0.37) <0.001
Non-academic 0.42 (0.35–0.49) 0.46 (0.37–0.54) 0.358
Target cells ≥50% – no. (%) 50 (68) 29 (57) <0.001
Agreement – j (95% CI)
All 0.31 (0.28–0.34) 0.38 (0.33–0.41) <0.001
Expert academic 0.33 (0.26–0.40) 0.55 (0.47–0.64) <0.001
Non-academic 0.27 (0.20–0.34) 0.33 (0.24–0.42) 0.127
Tissue core present – no. (%) 52 (70) 18 (35) <0.001
Agreement – j (95% CI)
All 0.37 (0.34–0.41) 0.14 (0.10–0.18) <0.001
Expert academic 0.41 (0.34–0.48) 0.08 (0.00–0.16) <0.001
Non-academic 0.26 (0.19–0.33) 0.04 (0.04 to 0.13) <0.001
Additional analysis possible – no. (%) 56 (76) 28 (55) <0.001
Agreement – j (95% CI)
All 0.47 (0.43–0.50) 0.42 (0.38–0.46) 0.016
Expert academic 0.51 (0.44–0.58) 0.43 (0.34–0.51) 0.042
Non-academic 0.38 (0.30–0.45) 0.38 (0.29–0.47) 0.593
CI, confidence interval; FNA, fine-needle aspiration; FNB, fine-needle biopsy.
Table 3 Diagnostic agreement of FNA and FNB per target lesion
Scored variablesAgreement j (95% CI) FNB (n = 74) FNA (n = 51) P-value
Bethesda classification
Pancreas 0.54 (0.51–0.58) 0.47 (0.43–0.52) <0.001
Lymph node 0.64 (0.61–0.67) 0.43 (0.39–0.47) <0.001
Presence of malignancy
Pancreas 0.64 (0.59–0.69) 0.60 (0.54–0.66) 0.114
Lymph node 0.84 (0.79–0.89) 0.58 (0.52–0.63) <0.001
CI, confidence interval; FNA, fine-needle aspiration; FNB, fine-needle biopsy.
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the presence of tissue cores signiﬁcantly improved diagnos-
tic accuracy (P = 0.003).
DISCUSSION
IN ADDITION TO the previously reported diagnosticbeneﬁt of a novel 20-G FNB over a commonly used 25-G
FNA needle, the present study shows that diagnostic
agreement is also higher for FNB than for FNA samples.
More importantly, agreement on FNB samples was higher
among pathologists from different backgrounds (academic
vs community practice) and with different levels of expe-
rience (high vs lower volume). The beneﬁt of FNB equally
applies to pancreatic and lymphatic target lesions. The
ﬁnding that FNB samples were of better quality and
harbored histology more often likely contributed to their
superior diagnostic performance.
Most studies on EUS-needle devices have been carried
out in expert high-volume centers. However, EUS-guided
tissue sampling is increasingly applied in lower-volume
centers. So far, few studies have evaluated the reproducibil-
ity of EUS-FNA/FNB results. Moreover, most of these
studies had a limited number of observers, concerned one
type of target lesion, or were carried out in an academic
practice only.20–24 Previous studies reported diagnostic
agreement rates ranging from moderate to excellent for
FNA (j = 0.45–0.89) and FNB (j = 0.61–0.94). Recently,
a promising study aimed to validate a novel scoring system
to further optimize diagnostic agreement among cytopathol-
ogists.24 Unfortunately, despite the fact that observers were
selected from tertiary centers, diagnostic agreement for
pancreatic FNA specimens was still suboptimal (j = 0.56).
Compared to these agreement rates, the 20-G FNB needle
performed well, especially when we take into account that
pathologists from all over the world were included,
academics and non-academics alike. The 20-G FNB needle
may thus contribute to improve reproducibility of EUS-
FNA/B diagnosis.
The ﬁrst explanation for better agreement on FNB
samples is its high tissue core rate, as the collection of
histology rather than cytology was positively associated
with higher agreement. This is supported by the ﬁnding
that the cytological yield of FNB was also higher than for
FNA, but only availability of tissue cores for histology, and
not cytology, contributed to a better diagnostic accuracy.
The importance of tissue core samples over cytological
samples to reach a correct diagnosis when using an FNB
needle has been previously described by others.20 Com-
pared to other FNB needles, the cytological yield of the
current 20-G FNB needle was also high.9,20,22,25–31
Whereas previous studies reported sufﬁcient cellularity in
19%–52%, in the current study, this was 68%. The only
device that provides higher histology and cytology rates is
the 19-G needle,22,25 which obtains cores in 88% of
samples and an adequate amount of loose target cells in
91%. However, the reported clinical applicability of being
Table 4 Diagnostic agreement on cytological and histological
specimens per needle type
Agreement j
(95% CI)
Cytology Histology P-
value
Bethesda classification
All samples
(n = 121)
0.51 (0.49–0.52) 0.60 (0.59–0.61) <0.001
FNA (n = 47) 0.49 (0.46–0.50) 0.52 (0.49–0.55) 0.432
FNB (n = 74) 0.52 (0.49–0.54) 0.62 (0.61–0.63) <0.001
Presence of malignancy
All samples
(n = 121)
0.76 (0.74–0.78) 0.97 (0.95–0.99) <0.001
FNA (n = 47) 0.73 (0.71–0.76) 0.89 (0.86–0.92) 0.002
FNB (n = 74) 0.78 (0.75–0.81) 0.99 (0.79–1.00) <0.001
CI, confidence interval; FNA, fine-needle aspiration; FNB, fine-needle
biopsy.
Table 5 Factors affecting diagnostic accuracy by univariate analysis
Diagnostic accuracyBethesda classification UnivariateOR
(95%CI)
P-value Diagnostic accuracy
for malignancy
UnivariateOR
(95%CI)
P-value
Pathologist experience Pathologist experience
Expert academic 0.96 (0.82–1.12) 0.587 Academic 0.88 (0.70–1.10) 0.250
Non-academic Non-academic
Presence of artifacts Presence of artifacts
No 1.45 (1.22–1.74) <0.001 No 1.34 (1.03–1.75) 0.030
Yes Yes
Type of tissue Type of tissue
Histology 0.55 (0.32–0.94) 0.030 Histology 0.39 (0.21–0.72) 0.003
Cytology Cytology
CI, confidence interval; OR, odds ratio.
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able to obtain tissue with the 19-G FNB needle (81%) is
much lower than with the 20-G FNB needle (99%).
Although the increased ﬂexibility of the 20-G FNB needle
is likely a major contributor to its better performance, other
needle design adjustments may also have improved the
tissue acquisition rate.32,33
Another quality parameter that may have contributed to
the high diagnostic agreement on samples obtained with
FNB is a low artifact rate. Although artifacts do not
necessarily decrease accuracy when abundant tissue is
collected, previous studies have shown that they may
hamper advanced genetic testing, for example.34 Interest-
ingly, agreement on the presence of artifacts was low for
both needles (although slightly better for FNB than for
FNA). This is in line with the fact that agreement on all
sample quality parameters was rather low, similar to reports
from others.21,24 This may result from a lack of EUS-sample
quality deﬁnitions. In the current study, we tried to minimize
this limitation by using the predeﬁned scoring system, as
proposed by the Papanicolaou Society of Cytopathology in
2014.18
There are several limitations to our study. First, each
academic pathologist brought and presented his or her own
slides. Although they too were blinded for the ﬁnal
outcome, we cannot exclude recall bias. However, this only
applied to a few cases per pathologist. Second, pathologists
assessed samples individually, whereas, in daily practice,
difﬁcult cases are often discussed among colleagues.
Therefore, interobserver agreements reported in the current
study may underestimate real-life reproducibility. Third, our
study involved pathologists from 10 centers from around the
world, whereas previous studies were conﬁned to no more
than ﬁve centers from the same geographical region. In the
absence of uniform guidelines for EUS-guided tissue
sampling and processing, it is inevitable that there are
geographical and institutional differences in the work-up of
specimens. These differences may have resulted in slight
differences in the appearance of specimens, which may have
hampered interpretation by pathologists not familiar with
certain preparation techniques. Last, it must be considered
that all samples were collected by expert endosonographers.
For an ideal assessment of the reproducibility of the
outcome of the ASPRO study, the study should be repeated
in low-volume centers, with less experienced endosonogra-
phers.
In conclusion, the present study demonstrates that the
novel 20-G FNB needle outperforms the 25-G FNA needle
in terms of diagnostic agreement, as its diagnostic superi-
ority is not limited by the expertise and experience of the
reviewing pathologist. Better sample quality and presence of
histology seem to be the determinants responsible for the
better diagnostic performance of the 20-G FNB needle.
Together with the favorable accuracy rates from the previous
ASPRO study, current ﬁndings advocate the use of the novel
20-G FNB needle in high- as well as in lower-volume EUS
centers.
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